Clinician-caregiver informant discrepancy is associated with sex, diagnosis age, and intervention use among autistic children / Margaret A. AZU in Autism, 29-3 (March 2025)  

Public ISBD [article]  inAutism > 29-3 (March 2025) . - p.614-626 Titre : Clinician-caregiver informant discrepancy is associated with sex, diagnosis age, and intervention use among autistic children Type de document : Texte imprimé et/ou numérique Auteurs : Margaret A. AZU, Auteur ; Gloria T. HAN, Auteur ; Julie M. WOLF, Auteur ; Adam J. NAPLES, Auteur ; Katarzyna CHAWARSKA, Auteur ; Geraldine DAWSON, Auteur ; Raphael A. BERNIER, Auteur ; Shafali S. JESTE, Auteur ; James D. DZIURA, Auteur ; Sara J. WEBB, Auteur ; Catherine A. SUGAR, Auteur ; Frederick SHIC, Auteur ; James C. MCPARTLAND, Auteur Article en page(s) : p.614-626 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Clinician and caregiver reports of autism features are both integral to receiving an autism diagnosis and appropriate intervention, yet informant discrepancies are present in clinical practice and may differ by demographic characteristics of the child and ... En ligne : https://dx.doi.org/10.1177/13623613241279999 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=550 [article] Clinician-caregiver informant discrepancy is associated with sex, diagnosis age, and intervention use among autistic children [Texte imprimé et/ou numérique] / Margaret A. AZU, Auteur ; Gloria T. HAN, Auteur ; Julie M. WOLF, Auteur ; Adam J. NAPLES, Auteur ; Katarzyna CHAWARSKA, Auteur ; Geraldine DAWSON, Auteur ; Raphael A. BERNIER, Auteur ; Shafali S. JESTE, Auteur ; James D. DZIURA, Auteur ; Sara J. WEBB, Auteur ; Catherine A. SUGAR, Auteur ; Frederick SHIC, Auteur ; James C. MCPARTLAND, Auteur . - p.614-626. Langues : Anglais (eng) in Autism > 29-3 (March 2025) . - p.614-626 Index. décimale : PER Périodiques Résumé : Clinician and caregiver reports of autism features are both integral to receiving an autism diagnosis and appropriate intervention, yet informant discrepancies are present in clinical practice and may differ by demographic characteristics of the child and ... En ligne : https://dx.doi.org/10.1177/13623613241279999 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=550

Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials / Susan FAJA in Autism Research, 16-5 (May 2023)  

Public ISBD [article]  inAutism Research > 16-5 (May 2023) . - p.981-996 Titre : Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials Type de document : Texte imprimé et/ou numérique Auteurs : Susan FAJA, Auteur ; Maura SABATOS-DEVITO, Auteur ; Aksheya SRIDHAR, Auteur ; Jocelyn L. KUHN, Auteur ; Julia I. NIKOLAEVA, Auteur ; Catherine A. SUGAR, Auteur ; Sara Jane WEBB, Auteur ; Raphael A. BERNIER, Auteur ; Linmarie SIKICH, Auteur ; Gerhard HELLEMANN, Auteur ; Damla SENTURK, Auteur ; Adam J. NAPLES, Auteur ; Frederick SHIC, Auteur ; April R. LEVIN, Auteur ; Helen A. SEOW, Auteur ; James D. DZIURA, Auteur ; Shafali S. JESTE, Auteur ; Katarzyna CHAWARSKA, Auteur ; Charles A. NELSON III, Auteur ; Geraldine DAWSON, Auteur ; James C. MCPARTLAND, Auteur ; Autism Biomarkers Consortium for Clinical TRIALS, Auteur Article en page(s) : p.981-996 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Abstract Clinical trials in autism spectrum disorder (ASD) often rely on clinician rating scales and parent surveys to measure autism-related features and social behaviors. To aid in the selection of these assessments for future clinical trials, the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) directly compared eight common instruments with respect to acquisition rates, sensitivity to group differences, equivalence across demographic sub-groups, convergent validity, and stability over a 6-week period. The sample included 280 children diagnosed with ASD (65 girls) and 119 neurotypical children (36 girls) aged from 6 to 11?years. Full scale IQ for ASD ranged from 60 to 150 and for neurotypical ranged from 86 to 150. Instruments measured clinician global assessment and autism-related behaviors, social communication abilities, adaptive function, and social withdrawal behavior. For each instrument, we examined only the scales that measured social or communication functioning. Data acquisition rates were at least 97.5% at T1 and 95.7% at T2. All scales distinguished diagnostic groups. Some scales significantly differed by participant and/or family demographic characteristics. Within the ASD group, most clinical instruments exhibited weak (? |0.1|) to moderate (? |0.4|) intercorrelations. Short-term stability was moderate (ICC: 0.5-0.75) to excellent (ICC: >0.9) within the ASD group. Variations in the degree of stability may inform viability for different contexts of use, such as identifying clinical subgroups for trials versus serving as a modifiable clinical outcome. All instruments were evaluated in terms of their advantages and potential concerns for use in clinical trials. En ligne : http://dx.doi.org/https://doi.org/10.1002/aur.2905 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=503 [article] Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials [Texte imprimé et/ou numérique] / Susan FAJA, Auteur ; Maura SABATOS-DEVITO, Auteur ; Aksheya SRIDHAR, Auteur ; Jocelyn L. KUHN, Auteur ; Julia I. NIKOLAEVA, Auteur ; Catherine A. SUGAR, Auteur ; Sara Jane WEBB, Auteur ; Raphael A. BERNIER, Auteur ; Linmarie SIKICH, Auteur ; Gerhard HELLEMANN, Auteur ; Damla SENTURK, Auteur ; Adam J. NAPLES, Auteur ; Frederick SHIC, Auteur ; April R. LEVIN, Auteur ; Helen A. SEOW, Auteur ; James D. DZIURA, Auteur ; Shafali S. JESTE, Auteur ; Katarzyna CHAWARSKA, Auteur ; Charles A. NELSON III, Auteur ; Geraldine DAWSON, Auteur ; James C. MCPARTLAND, Auteur ; Autism Biomarkers Consortium for Clinical TRIALS, Auteur . - p.981-996. Langues : Anglais (eng) in Autism Research > 16-5 (May 2023) . - p.981-996 Index. décimale : PER Périodiques Résumé : Abstract Clinical trials in autism spectrum disorder (ASD) often rely on clinician rating scales and parent surveys to measure autism-related features and social behaviors. To aid in the selection of these assessments for future clinical trials, the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) directly compared eight common instruments with respect to acquisition rates, sensitivity to group differences, equivalence across demographic sub-groups, convergent validity, and stability over a 6-week period. The sample included 280 children diagnosed with ASD (65 girls) and 119 neurotypical children (36 girls) aged from 6 to 11?years. Full scale IQ for ASD ranged from 60 to 150 and for neurotypical ranged from 86 to 150. Instruments measured clinician global assessment and autism-related behaviors, social communication abilities, adaptive function, and social withdrawal behavior. For each instrument, we examined only the scales that measured social or communication functioning. Data acquisition rates were at least 97.5% at T1 and 95.7% at T2. All scales distinguished diagnostic groups. Some scales significantly differed by participant and/or family demographic characteristics. Within the ASD group, most clinical instruments exhibited weak (? |0.1|) to moderate (? |0.4|) intercorrelations. Short-term stability was moderate (ICC: 0.5-0.75) to excellent (ICC: >0.9) within the ASD group. Variations in the degree of stability may inform viability for different contexts of use, such as identifying clinical subgroups for trials versus serving as a modifiable clinical outcome. All instruments were evaluated in terms of their advantages and potential concerns for use in clinical trials. En ligne : http://dx.doi.org/https://doi.org/10.1002/aur.2905 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=503

Patterns of intervention utilization among school-aged children on the autism spectrum: Findings from a multi-site research consortium / Aksheya SRIDHAR in Research in Autism Spectrum Disorders, 94 (June 2022)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 94 (June 2022) . - 101950 Titre : Patterns of intervention utilization among school-aged children on the autism spectrum: Findings from a multi-site research consortium Type de document : Texte imprimé et/ou numérique Auteurs : Aksheya SRIDHAR, Auteur ; Jocelyn KUHN, Auteur ; Susan FAJA, Auteur ; Maura SABATOS-DEVITO, Auteur ; Julia I. NIKOLAEVA, Auteur ; Geraldine DAWSON, Auteur ; Charles A. NELSON, Auteur ; Sara J. WEBB, Auteur ; Raphael BERNIER, Auteur ; Shafali JESTE, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A. SUGAR, Auteur ; Frederick SHIC, Auteur ; Adam NAPLES, Auteur ; James DZIURA, Auteur ; James C. MCPARTLAND, Auteur ; THE A. B. C. C. T. CONSORTIUM, Auteur Article en page(s) : 101950 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Child characteristics  Family characteristics  Geographical location  Intervention use Index. décimale : PER Périodiques Résumé : When designing and interpreting results from clinical trials evaluating treatments for children on the autism spectrum, a complicating factor is that most children receive a range of concurrent treatments. Thus, it is important to better understand the types and hours of interventions that participants typically receive as part of standard of care, as well as to understand the child, family, and geographic factors that are associated with different patterns of service utilization. In this multi-site study, we interviewed 280 caregivers of 6-to-11-year-old school-aged children on the autism spectrum about the types and amounts of interventions their children received in the prior 6 weeks. Reported interventions were coded as ?evidence-based practice? or ?other interventions,? reflecting the level of empirical support. Results indicated that children received a variety of interventions with varying levels of empirical evidence and a wide range of hours (0?79.3 h/week). Children with higher autism symptom levels, living in particular states, and who identified as non-Hispanic received more evidence-based intervention hours. Higher parental education level related to more hours of other interventions. Children who were younger, had lower cognitive ability, and with higher autism symptom levels received a greater variety of interventions overall. Thus, based on our findings, it would seem prudent when designing clinical trials to take into consideration a variety of factors including autism symptom levels, age, cognitive ability, ethnicity, parent education and geographic location. Future research should continue to investigate the ethnic, racial, and socioeconomic influences on school-aged intervention services. En ligne : https://doi.org/10.1016/j.rasd.2022.101950 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=476 [article] Patterns of intervention utilization among school-aged children on the autism spectrum: Findings from a multi-site research consortium [Texte imprimé et/ou numérique] / Aksheya SRIDHAR, Auteur ; Jocelyn KUHN, Auteur ; Susan FAJA, Auteur ; Maura SABATOS-DEVITO, Auteur ; Julia I. NIKOLAEVA, Auteur ; Geraldine DAWSON, Auteur ; Charles A. NELSON, Auteur ; Sara J. WEBB, Auteur ; Raphael BERNIER, Auteur ; Shafali JESTE, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A. SUGAR, Auteur ; Frederick SHIC, Auteur ; Adam NAPLES, Auteur ; James DZIURA, Auteur ; James C. MCPARTLAND, Auteur ; THE A. B. C. C. T. CONSORTIUM, Auteur . - 101950. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 94 (June 2022) . - 101950 Mots-clés : Autism spectrum disorder  Child characteristics  Family characteristics  Geographical location  Intervention use Index. décimale : PER Périodiques Résumé : When designing and interpreting results from clinical trials evaluating treatments for children on the autism spectrum, a complicating factor is that most children receive a range of concurrent treatments. Thus, it is important to better understand the types and hours of interventions that participants typically receive as part of standard of care, as well as to understand the child, family, and geographic factors that are associated with different patterns of service utilization. In this multi-site study, we interviewed 280 caregivers of 6-to-11-year-old school-aged children on the autism spectrum about the types and amounts of interventions their children received in the prior 6 weeks. Reported interventions were coded as ?evidence-based practice? or ?other interventions,? reflecting the level of empirical support. Results indicated that children received a variety of interventions with varying levels of empirical evidence and a wide range of hours (0?79.3 h/week). Children with higher autism symptom levels, living in particular states, and who identified as non-Hispanic received more evidence-based intervention hours. Higher parental education level related to more hours of other interventions. Children who were younger, had lower cognitive ability, and with higher autism symptom levels received a greater variety of interventions overall. Thus, based on our findings, it would seem prudent when designing clinical trials to take into consideration a variety of factors including autism symptom levels, age, cognitive ability, ethnicity, parent education and geographic location. Future research should continue to investigate the ethnic, racial, and socioeconomic influences on school-aged intervention services. En ligne : https://doi.org/10.1016/j.rasd.2022.101950 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=476

The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials / Frederick SHIC in Molecular Autism, 13 (2022)  

Public ISBD [article]  inMolecular Autism > 13 (2022) . - 15 p. Titre : The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials Type de document : Texte imprimé et/ou numérique Auteurs : Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Erin C. BARNEY, Auteur ; Shou An CHANG, Auteur ; Beibin LI, Auteur ; Takumi MCALLISTER, Auteur ; Minah KIM, Auteur ; Kelsey J. DOMMER, Auteur ; Simone HASSELMO, Auteur ; Adham ATYABI, Auteur ; Quan WANG, Auteur ; Gerhard HELLEMAN, Auteur ; April R. LEVIN, Auteur ; Helen SEOW, Auteur ; Raphael BERNIER, Auteur ; Katarzyna CHARWASKA, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali SPURLING JESTE, Auteur ; Scott P. JOHNSON, Auteur ; Michael MURIAS, Auteur ; Charles A. NELSON, Auteur ; Maura SABATOS-DEVITO, Auteur ; Damla SENTURK, Auteur ; Catherine A. SUGAR, Auteur ; Sara J. WEBB, Auteur ; James C. MCPARTLAND, Auteur Article en page(s) : 15 p. Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis/psychology  Autistic Disorder/diagnosis  Biomarkers  Child  Eye Movements  Eye-Tracking Technology  Humans  Autism spectrum disorder  Biological motion  Eye tracking  Face processing  Gaze pattern  Visual attention Index. décimale : PER Périodiques Résumé : BACKGROUND: Eye tracking (ET) is a powerful methodology for studying attentional processes through quantification of eye movements. The precision, usability, and cost-effectiveness of ET render it a promising platform for developing biomarkers for use in clinical trials for autism spectrum disorder (ASD). METHODS: The autism biomarkers consortium for clinical trials conducted a multisite, observational study of 6-11-year-old children with ASD (n=280) and typical development (TD, n=119). The ET battery included: Activity Monitoring, Social Interactive, Static Social Scenes, Biological Motion Preference, and Pupillary Light Reflex tasks. A priori, gaze to faces in Activity Monitoring, Social Interactive, and Static Social Scenes tasks were aggregated into an Oculomotor Index of Gaze to Human Faces (OMI) as the primary outcome measure. This work reports on fundamental biomarker properties (data acquisition rates, construct validity, six-week stability, group discrimination, and clinical relationships) derived from these assays that serve as a base for subsequent development of clinical trial biomarker applications. RESULTS: All tasks exhibited excellent acquisition rates, met expectations for construct validity, had moderate or high six-week stabilities, and highlighted subsets of the ASD group with distinct biomarker performance. Within ASD, higher OMI was associated with increased memory for faces, decreased autism symptom severity, and higher verbal IQ and pragmatic communication skills. LIMITATIONS: No specific interventions were administered in this study, limiting information about how ET biomarkers track or predict outcomes in response to treatment. This study did not consider co-occurrence of psychiatric conditions nor specificity in comparison with non-ASD special populations, therefore limiting our understanding of the applicability of outcomes to specific clinical contexts-of-use. Research-grade protocols and equipment were used; further studies are needed to explore deployment in less standardized contexts. CONCLUSIONS: All ET tasks met expectations regarding biomarker properties, with strongest performance for tasks associated with attention to human faces and weakest performance associated with biological motion preference. Based on these data, the OMI has been accepted to the FDA's Biomarker Qualification program, providing a path for advancing efforts to develop biomarkers for use in clinical trials. En ligne : http://dx.doi.org/10.1186/s13229-021-00482-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477 [article] The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials [Texte imprimé et/ou numérique] / Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Erin C. BARNEY, Auteur ; Shou An CHANG, Auteur ; Beibin LI, Auteur ; Takumi MCALLISTER, Auteur ; Minah KIM, Auteur ; Kelsey J. DOMMER, Auteur ; Simone HASSELMO, Auteur ; Adham ATYABI, Auteur ; Quan WANG, Auteur ; Gerhard HELLEMAN, Auteur ; April R. LEVIN, Auteur ; Helen SEOW, Auteur ; Raphael BERNIER, Auteur ; Katarzyna CHARWASKA, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali SPURLING JESTE, Auteur ; Scott P. JOHNSON, Auteur ; Michael MURIAS, Auteur ; Charles A. NELSON, Auteur ; Maura SABATOS-DEVITO, Auteur ; Damla SENTURK, Auteur ; Catherine A. SUGAR, Auteur ; Sara J. WEBB, Auteur ; James C. MCPARTLAND, Auteur . - 15 p. Langues : Anglais (eng) in Molecular Autism > 13 (2022) . - 15 p. Mots-clés : Autism Spectrum Disorder/diagnosis/psychology  Autistic Disorder/diagnosis  Biomarkers  Child  Eye Movements  Eye-Tracking Technology  Humans  Autism spectrum disorder  Biological motion  Eye tracking  Face processing  Gaze pattern  Visual attention Index. décimale : PER Périodiques Résumé : BACKGROUND: Eye tracking (ET) is a powerful methodology for studying attentional processes through quantification of eye movements. The precision, usability, and cost-effectiveness of ET render it a promising platform for developing biomarkers for use in clinical trials for autism spectrum disorder (ASD). METHODS: The autism biomarkers consortium for clinical trials conducted a multisite, observational study of 6-11-year-old children with ASD (n=280) and typical development (TD, n=119). The ET battery included: Activity Monitoring, Social Interactive, Static Social Scenes, Biological Motion Preference, and Pupillary Light Reflex tasks. A priori, gaze to faces in Activity Monitoring, Social Interactive, and Static Social Scenes tasks were aggregated into an Oculomotor Index of Gaze to Human Faces (OMI) as the primary outcome measure. This work reports on fundamental biomarker properties (data acquisition rates, construct validity, six-week stability, group discrimination, and clinical relationships) derived from these assays that serve as a base for subsequent development of clinical trial biomarker applications. RESULTS: All tasks exhibited excellent acquisition rates, met expectations for construct validity, had moderate or high six-week stabilities, and highlighted subsets of the ASD group with distinct biomarker performance. Within ASD, higher OMI was associated with increased memory for faces, decreased autism symptom severity, and higher verbal IQ and pragmatic communication skills. LIMITATIONS: No specific interventions were administered in this study, limiting information about how ET biomarkers track or predict outcomes in response to treatment. This study did not consider co-occurrence of psychiatric conditions nor specificity in comparison with non-ASD special populations, therefore limiting our understanding of the applicability of outcomes to specific clinical contexts-of-use. Research-grade protocols and equipment were used; further studies are needed to explore deployment in less standardized contexts. CONCLUSIONS: All ET tasks met expectations regarding biomarker properties, with strongest performance for tasks associated with attention to human faces and weakest performance associated with biological motion preference. Based on these data, the OMI has been accepted to the FDA's Biomarker Qualification program, providing a path for advancing efforts to develop biomarkers for use in clinical trials. En ligne : http://dx.doi.org/10.1186/s13229-021-00482-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477

The Selective Social Attention task in children with autism spectrum disorder: Results from the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) feasibility study / Erin C. BARNEY ; Adam J. NAPLES ; Kelsey J. DOMMER ; Shou An CHANG ; Beibin LI ; Takumi MCALLISTER ; Adham ATYABI ; Quan WANG ; Raphael BERNIER ; Geraldine DAWSON ; James DZIURA ; Susan FAJA ; Shafali Spurling JESTE ; Michael MURIAS ; Scott P. JOHNSON ; Maura SABATOS-DEVITO ; Gerhard HELLEMAN ; Damla SENTURK ; Catherine A. SUGAR ; Sara Jane WEBB ; James C. MCPARTLAND ; Katarzyna CHAWARSKA ; The Autism Biomarkers Consortium for Clinical TRIALS in Autism Research, 16-11 (November 2023)  

Public ISBD [article]  inAutism Research > 16-11 (November 2023) . - p.2150-2159 Titre : The Selective Social Attention task in children with autism spectrum disorder: Results from the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) feasibility study Type de document : Texte imprimé et/ou numérique Auteurs : Erin C. BARNEY, Auteur ; Adam J. NAPLES, Auteur ; Kelsey J. DOMMER, Auteur ; Shou An CHANG, Auteur ; Beibin LI, Auteur ; Takumi MCALLISTER, Auteur ; Adham ATYABI, Auteur ; Quan WANG, Auteur ; Raphael BERNIER, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali Spurling JESTE, Auteur ; Michael MURIAS, Auteur ; Scott P. JOHNSON, Auteur ; Maura SABATOS-DEVITO, Auteur ; Gerhard HELLEMAN, Auteur ; Damla SENTURK, Auteur ; Catherine A. SUGAR, Auteur ; Sara Jane WEBB, Auteur ; James C. MCPARTLAND, Auteur ; Katarzyna CHAWARSKA, Auteur ; The Autism Biomarkers Consortium for Clinical TRIALS, Auteur Article en page(s) : p.2150-2159 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Abstract The Selective Social Attention (SSA) task is a brief eye-tracking task involving experimental conditions varying along socio-communicative axes. Traditionally the SSA has been used to probe socially-specific attentional patterns in infants and toddlers who develop autism spectrum disorder (ASD). This current work extends these findings to preschool and school-age children. Children 4- to 12-years-old with ASD (N=23) and a typically-developing comparison group (TD; N=25) completed the SSA task as well as standardized clinical assessments. Linear mixed models examined group and condition effects on two outcome variables: percent of time spent looking at the scene relative to scene presentation time (%Valid), and percent of time looking at the face relative to time spent looking at the scene (%Face). Age and IQ were included as covariates. Outcome variables' relationships to clinical data were assessed via correlation analysis. The ASD group, compared to the TD group, looked less at the scene and focused less on the actress' face during the most socially-engaging experimental conditions. Additionally, within the ASD group, %Face negatively correlated with SRS total T-scores with a particularly strong negative correlation with the Autistic Mannerism subscale T-score. These results highlight the extensibility of the SSA to older children with ASD, including replication of between-group differences previously seen in infants and toddlers, as well as its ability to capture meaningful clinical variation within the autism spectrum across a wide developmental span inclusive of preschool and school-aged children. The properties suggest that the SSA may have broad potential as a biomarker for ASD. En ligne : https://doi.org/10.1002/aur.3026 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=517 [article] The Selective Social Attention task in children with autism spectrum disorder: Results from the Autism Biomarkers Consortium for Clinical Trials (ABC-CT) feasibility study [Texte imprimé et/ou numérique] / Erin C. BARNEY, Auteur ; Adam J. NAPLES, Auteur ; Kelsey J. DOMMER, Auteur ; Shou An CHANG, Auteur ; Beibin LI, Auteur ; Takumi MCALLISTER, Auteur ; Adham ATYABI, Auteur ; Quan WANG, Auteur ; Raphael BERNIER, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali Spurling JESTE, Auteur ; Michael MURIAS, Auteur ; Scott P. JOHNSON, Auteur ; Maura SABATOS-DEVITO, Auteur ; Gerhard HELLEMAN, Auteur ; Damla SENTURK, Auteur ; Catherine A. SUGAR, Auteur ; Sara Jane WEBB, Auteur ; James C. MCPARTLAND, Auteur ; Katarzyna CHAWARSKA, Auteur ; The Autism Biomarkers Consortium for Clinical TRIALS, Auteur . - p.2150-2159. Langues : Anglais (eng) in Autism Research > 16-11 (November 2023) . - p.2150-2159 Index. décimale : PER Périodiques Résumé : Abstract The Selective Social Attention (SSA) task is a brief eye-tracking task involving experimental conditions varying along socio-communicative axes. Traditionally the SSA has been used to probe socially-specific attentional patterns in infants and toddlers who develop autism spectrum disorder (ASD). This current work extends these findings to preschool and school-age children. Children 4- to 12-years-old with ASD (N=23) and a typically-developing comparison group (TD; N=25) completed the SSA task as well as standardized clinical assessments. Linear mixed models examined group and condition effects on two outcome variables: percent of time spent looking at the scene relative to scene presentation time (%Valid), and percent of time looking at the face relative to time spent looking at the scene (%Face). Age and IQ were included as covariates. Outcome variables' relationships to clinical data were assessed via correlation analysis. The ASD group, compared to the TD group, looked less at the scene and focused less on the actress' face during the most socially-engaging experimental conditions. Additionally, within the ASD group, %Face negatively correlated with SRS total T-scores with a particularly strong negative correlation with the Autistic Mannerism subscale T-score. These results highlight the extensibility of the SSA to older children with ASD, including replication of between-group differences previously seen in infants and toddlers, as well as its ability to capture meaningful clinical variation within the autism spectrum across a wide developmental span inclusive of preschool and school-aged children. The properties suggest that the SSA may have broad potential as a biomarker for ASD. En ligne : https://doi.org/10.1002/aur.3026 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=517

Time Reproduction Performance Is Associated With Age and Working Memory in High-Functioning Youth With Autism Spectrum Disorder / Laurie A. BRENNER in Autism Research, 8-1 (February 2015)  

Permalink

---

1 (1 - 6 / 6)